Tag: actinic keratosis market outlook

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Actinic Keratosis Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The actinic keratosis market has experienced robust expansion lately, projected to increase from $8.42 billion in 2025 to $8.91 billion in 2026, reflecting a compound annual growth rate of 5.8%. This upward trend in the historical period stems from factors such as increased UV radiation exposure and a higher occurrence of sunburns, coupled with a scarcity of potent topical treatments, a rise in skin cancer cases, the development of dermatological healthcare facilities, and the utilization of standard surgical interventions.

The market for actinic keratosis is poised for significant expansion in the coming years, projected to reach $11.06 billion by 2030, reflecting a compound annual growth rate of 5.6%. This anticipated growth trajectory is fueled by several key factors, including advancements in photodynamic therapies, a greater embrace of combined topical and procedural treatment approaches, the proliferation of hospital and dermatology clinic facilities, heightened public consciousness regarding the importance of early intervention, and the emergence of novel treatment options for home use. During this forecast period, dominant market trends will include a heightened emphasis on sun protection and skin health awareness, a growing acceptance of non-invasive photodynamic therapy, increased utilization of topical treatments for early-stage actinic keratosis, the expansion of both dermatology clinic services and at-home care solutions, and a discernible shift towards combination therapy preferences.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21077&type=smp

Actinic Keratosis Market Growth Drivers: What Factors Are Accelerating Expansion?

The rise in instances of severe sunburn is anticipated to fuel the expansion of the actinic keratosis market. These intense skin burns, stemming from excessive ultraviolet (UV) radiation exposure, manifest as redness, discomfort, swelling, and occasionally blistering. Factors contributing to sunburn include extended periods under UV rays, inadequate sun protection, increased outdoor pursuits during peak UV times, and escalating global temperatures attributed to climate change. Sunburns contribute to actinic keratosis by damaging the DNA within skin cells via UV radiation, leading to mutations that impair normal cellular activity and consequently foster the development of precancerous lesions, particularly with repeated or prolonged sun exposure. As an illustration, data from Melanoma Focus, a UK charity, revealed that in the 2022-23 period, there were 201 hospital admissions related to sunburn, a figure that encompassed 89 children and 25 infants under the age of one. The same report indicated that 66% of UK adults aged 16-65 recalled experiencing sunburn during their childhood, with 65% of this group having endured a severe sunburn involving blisters at least once; this proportion increased to 77% among individuals with fair, pale, or white skin tones. Consequently, the escalating frequency of severe sunburns is acting as a catalyst for the growth observed in the actinic keratosis market.

Actinic Keratosis Market Segment Analysis Highlighting Growth Areas

The actinic keratosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatment, Surgical Procedure, Photodynamic Therapy, Other Treatment Types

2) By Distribution Channels: Hospital Pharmacies, Drug Stores And Retail Pharmacies

3) By End-User: Hospitals, Dermatology Clinics, Homecare Settings, Other End-Users

Subsegments:

1) By Topical Treatment: 5-Fluorouracil (5-FU), Imiquimod, Diclofenac

2) By Surgical Procedure: Cryotherapy, Curettage And Electrodessication

3) By Photodynamic Therapy: Aminolevulinic Acid (ALA) Plus Light Therapy, Methyl Aminolevulinate (MAL) Plus Light Therapy

4) By Other Treatment Types: Laser Therapy, Combination Therapies

Actinic Keratosis Market Trends: What Is Shaping Future Industry Growth?

Companies prominent in the actinic keratosis market are concentrating their efforts on formulating topical applications designed for the precise destruction of precancerous skin abnormalities, aiming to minimize the likelihood of the condition’s return and boost patient adherence through abbreviated treatment periods accompanied by enhanced safety characteristics. These topical preparations, typically in the form of medicated creams or gels, are administered directly onto the compromised skin and feature active components like tirbanibulin, which function by specifically addressing aberrant keratinocytes to manage pre-malignant lesions. A noteworthy development occurred in June of 2024 when Almirall SA, a biopharmaceutical enterprise headquartered in Spain, secured approval from the U.S. Food and Drug Administration (FDA) for a supplementary new drug application (sNDA), thereby expanding the permissible application area of its therapeutic agent, Klisyri, to cover up to 100 square centimeters. Klisyri, a 1% ointment formulation of tirbanibulin, operates as a microtubule inhibitor, engineered to impede the proliferation of atypical keratinocytes, leading to a reduction in both the quantity and dimensions of precancerous lesions indicative of actinic keratosis on the facial or cranial regions.

Actinic Keratosis Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the actinic keratosis market are Galderma SA, LEO Pharma A/S, Almirall S.A., Bausch Health Companies Inc., Perrigo Company plc, Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GSK plc, Amgen Inc., Incyte Corporation, Aclaris Therapeutics Inc., Biofrontera AG, Hill Dermaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Viatris Inc.

Access The Complete Actinic Keratosis Market Report:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

Actinic Keratosis Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the actinic keratosis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Actinic Keratosis Market Become By 2030 Compared To 2026?

The actinic keratosis market has experienced substantial growth in recent years. It is anticipated to increase from $8.42 billion in 2025 to $8.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be attributed to rising uv exposure and sunburn incidence, limited availability of effective topical agents, increasing skin cancer prevalence, growing dermatology infrastructure, and adoption of conventional surgical procedures.

The actinic keratosis market is projected to experience robust expansion in the upcoming years. This market is anticipated to reach a value of $11.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. Several factors are expected to fuel this growth during the forecast period, including the advancement of photodynamic therapies, a rise in the application of combined topical and procedural treatments, the broadening of hospital and dermatology clinic infrastructures, growing consumer understanding of the importance of early intervention, and the launch of novel homecare treatment options. Key trends anticipated during this period encompass heightened awareness concerning sun protection and overall skin health, an uptick in the adoption of non-invasive photodynamic therapy, an increase in the use of topical therapeutics for early-stage actinic keratosis, the expansion of dermatology clinics and homecare solutions, and a growing inclination towards combination therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21077&type=smp

Which Growth Drivers Are Expected To Support The Actinic Keratosis Market Forward?

A rise in severe sunburn instances is anticipated to stimulate the expansion of the actinic keratosis market moving ahead. These are intense skin burns that occur from overexposure to ultraviolet (UV) radiation, leading to symptoms like redness, discomfort, swelling, and occasionally blisters. Factors contributing to sunburns include extended exposure to ultraviolet (UV) radiation, inadequate sun protection, greater engagement in outdoor pursuits during peak UV times, and warmer temperatures from climate change. Sunburns contribute to actinic keratosis by inflicting DNA damage in skin cells via ultraviolet (UV) radiation, which generates mutations that impair typical cell function and pave the way for precancerous lesions, particularly with recurrent or extended sun exposure. As an illustration, data from May 2024 by Melanoma Focus, a UK-based charity, indicated that during 2022-23, 201 hospital admissions were linked to sunburn, comprising 89 children and 25 babies less than a year old. Furthermore, the charity discovered that 66% of UK adults aged 16-65 recalled experiencing sunburn during childhood, with 65% of these individuals having suffered severe sunburns accompanied by blisters on at least one occasion. This proportion climbed to 77% for individuals possessing light, pale, or white skin. Consequently, the growing prevalence of severe sunburns is fueling the expansion of the actinic keratosis market.

Which Segment-Based Categories Are Covered In The Actinic Keratosis Market?

The actinic keratosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatment, Surgical Procedure, Photodynamic Therapy, Other Treatment Types

2) By Distribution Channels: Hospital Pharmacies, Drug Stores And Retail Pharmacies

3) By End-User: Hospitals, Dermatology Clinics, Homecare Settings, Other End-Users

Subsegments:

1) By Topical Treatment: 5-Fluorouracil (5-FU), Imiquimod, Diclofenac

2) By Surgical Procedure: Cryotherapy, Curettage And Electrodessication

3) By Photodynamic Therapy: Aminolevulinic Acid (ALA) Plus Light Therapy, Methyl Aminolevulinate (MAL) Plus Light Therapy

4) By Other Treatment Types: Laser Therapy, Combination Therapies

Which Trends Are Supporting The Evolution Of The Actinic Keratosis Market?

Major companies operating in the actinic keratosis market are focusing on developing topical ointments to effectively target and eliminate precancerous lesions, reduce recurrence rates, and enhance patient compliance with shorter treatment durations and improved safety profiles. Topical ointments are medicated creams or gels applied directly to the affected skin with active ingredients such as tirbanibulin, which work by targeting abnormal keratinocytes to treat precancerous lesions. For instance, in June 2024, Almirall SA, a Spain-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) to expand the use area for its drug, Klisyri, to up to 100 cm2. Klisyri (tirbanibulin) 1% ointment is a microtubule inhibitor, designed to prevent the proliferation of abnormal keratinocytes, effectively reducing the number and size of precancerous lesions for the treatment of actinic keratosis (AK) on the face or scalp.

Which Organizations Are Involved In The Actinic Keratosis Market?

Major companies operating in the actinic keratosis market are Galderma SA, LEO Pharma A/S, Almirall S.A., Bausch Health Companies Inc., Perrigo Company plc, Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GSK plc, Amgen Inc., Incyte Corporation, Aclaris Therapeutics Inc., Biofrontera AG, Hill Dermaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Viatris Inc.

Access The Complete Actinic Keratosis Market Report:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

Which Region Commands The Largest Share Of The Actinic Keratosis Market?

North America was the largest region in the actinic keratosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Actinic Keratosis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21077&type=smp

Browse Through More Reports Similar to the Global Actinic Keratosis Market 2026, By The Business Research Company

Neurotrophic Keratitis Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Scleroderma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Keloids Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Actinic Keratosis Market Become By 2030 Compared To 2026?

The actinic keratosis market has experienced substantial growth in recent years. It is anticipated to increase from $8.42 billion in 2025 to $8.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be attributed to rising uv exposure and sunburn incidence, limited availability of effective topical agents, increasing skin cancer prevalence, growing dermatology infrastructure, and adoption of conventional surgical procedures.

The actinic keratosis market is projected to experience robust expansion in the upcoming years. This market is anticipated to reach a value of $11.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. Several factors are expected to fuel this growth during the forecast period, including the advancement of photodynamic therapies, a rise in the application of combined topical and procedural treatments, the broadening of hospital and dermatology clinic infrastructures, growing consumer understanding of the importance of early intervention, and the launch of novel homecare treatment options. Key trends anticipated during this period encompass heightened awareness concerning sun protection and overall skin health, an uptick in the adoption of non-invasive photodynamic therapy, an increase in the use of topical therapeutics for early-stage actinic keratosis, the expansion of dermatology clinics and homecare solutions, and a growing inclination towards combination therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21077&type=smp

Which Growth Drivers Are Expected To Support The Actinic Keratosis Market Forward?

A rise in severe sunburn instances is anticipated to stimulate the expansion of the actinic keratosis market moving ahead. These are intense skin burns that occur from overexposure to ultraviolet (UV) radiation, leading to symptoms like redness, discomfort, swelling, and occasionally blisters. Factors contributing to sunburns include extended exposure to ultraviolet (UV) radiation, inadequate sun protection, greater engagement in outdoor pursuits during peak UV times, and warmer temperatures from climate change. Sunburns contribute to actinic keratosis by inflicting DNA damage in skin cells via ultraviolet (UV) radiation, which generates mutations that impair typical cell function and pave the way for precancerous lesions, particularly with recurrent or extended sun exposure. As an illustration, data from May 2024 by Melanoma Focus, a UK-based charity, indicated that during 2022-23, 201 hospital admissions were linked to sunburn, comprising 89 children and 25 babies less than a year old. Furthermore, the charity discovered that 66% of UK adults aged 16-65 recalled experiencing sunburn during childhood, with 65% of these individuals having suffered severe sunburns accompanied by blisters on at least one occasion. This proportion climbed to 77% for individuals possessing light, pale, or white skin. Consequently, the growing prevalence of severe sunburns is fueling the expansion of the actinic keratosis market.

Which Segment-Based Categories Are Covered In The Actinic Keratosis Market?

The actinic keratosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatment, Surgical Procedure, Photodynamic Therapy, Other Treatment Types

2) By Distribution Channels: Hospital Pharmacies, Drug Stores And Retail Pharmacies

3) By End-User: Hospitals, Dermatology Clinics, Homecare Settings, Other End-Users

Subsegments:

1) By Topical Treatment: 5-Fluorouracil (5-FU), Imiquimod, Diclofenac

2) By Surgical Procedure: Cryotherapy, Curettage And Electrodessication

3) By Photodynamic Therapy: Aminolevulinic Acid (ALA) Plus Light Therapy, Methyl Aminolevulinate (MAL) Plus Light Therapy

4) By Other Treatment Types: Laser Therapy, Combination Therapies

Which Trends Are Supporting The Evolution Of The Actinic Keratosis Market?

Major companies operating in the actinic keratosis market are focusing on developing topical ointments to effectively target and eliminate precancerous lesions, reduce recurrence rates, and enhance patient compliance with shorter treatment durations and improved safety profiles. Topical ointments are medicated creams or gels applied directly to the affected skin with active ingredients such as tirbanibulin, which work by targeting abnormal keratinocytes to treat precancerous lesions. For instance, in June 2024, Almirall SA, a Spain-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) to expand the use area for its drug, Klisyri, to up to 100 cm2. Klisyri (tirbanibulin) 1% ointment is a microtubule inhibitor, designed to prevent the proliferation of abnormal keratinocytes, effectively reducing the number and size of precancerous lesions for the treatment of actinic keratosis (AK) on the face or scalp.

Which Organizations Are Involved In The Actinic Keratosis Market?

Major companies operating in the actinic keratosis market are Galderma SA, LEO Pharma A/S, Almirall S.A., Bausch Health Companies Inc., Perrigo Company plc, Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GSK plc, Amgen Inc., Incyte Corporation, Aclaris Therapeutics Inc., Biofrontera AG, Hill Dermaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Viatris Inc.

Access The Complete Actinic Keratosis Market Report:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

Which Region Commands The Largest Share Of The Actinic Keratosis Market?

North America was the largest region in the actinic keratosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Actinic Keratosis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21077&type=smp

Browse Through More Reports Similar to the Global Actinic Keratosis Market 2026, By The Business Research Company

Neurotrophic Keratitis Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Scleroderma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Keloids Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Actinic Keratosis Market In 2026 And 2030?

The actinic keratosis market has shown strong growth in recent years. It is projected to increase from $8.42 billion in 2025 to $8.91 billion in 2026, progressing at a compound annual growth rate (CAGR) of 5.8%. This expansion in past periods can be attributed to factors such as rising UV exposure and sunburn incidence, the limited availability of effective topical agents, an increasing prevalence of skin cancer, the growth of dermatology infrastructure, and the adoption of conventional surgical procedures.

The actinic keratosis market is projected to experience robust expansion over the coming years, with its valuation expected to reach $11.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This anticipated growth can be attributed to several factors, including the development of advanced photodynamic therapies, an increasing application of combined topical and procedural treatments, the expansion of hospital and dermatology clinic networks, heightened consumer awareness regarding early intervention, and the introduction of innovative homecare treatment solutions. Key trends influencing the market during the forecast period involve a growing emphasis on sun protection and skin health awareness, the rising adoption of non-invasive photodynamic therapy, an increase in the usage of topical therapeutics for early-stage actinic keratosis, the proliferation of dermatology clinics and homecare treatment options, and a growing preference for combination therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

What Factors Are Contributing To The Growth Of The Actinic Keratosis Market?

The actinic keratosis market is anticipated to expand due to the rising incidence of severe sunburns. These intense skin burns, known as severe sunburns, stem from overexposure to ultraviolet (UV) radiation, leading to symptoms such as redness, pain, swelling, and occasionally blisters. Contributing factors to sunburns include extended exposure to ultraviolet (UV) radiation, insufficient sun protection, more outdoor pursuits during intense UV periods, and increasing temperatures resulting from climate change. Sunburns induce actinic keratosis by inflicting DNA damage in skin cells via ultraviolet (UV) radiation, which creates mutations that impede normal cellular function, subsequently forming precancerous lesions, particularly after recurrent or prolonged sun exposure. For example, data from May 2024, provided by Melanoma Focus, a UK-based charity, indicates that during 2022-23, 201 hospital admissions were linked to sunburns, comprising 89 children and 25 babies under one year old. Furthermore, the charity discovered that 66% of UK adults aged 16-65 recalled having sunburns in childhood, with 65% of these individuals enduring severe sunburns accompanied by blisters at least once. This percentage climbed to 77% for individuals possessing light, pale, or white skin. Consequently, the growing incidence of severe sunburns is fueling the expansion of the actinic keratosis market.

How Are Segments Identified Within The Actinic Keratosis Market Segment Framework?

The actinic keratosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatment, Surgical Procedure, Photodynamic Therapy, Other Treatment Types

2) By Distribution Channels: Hospital Pharmacies, Drug Stores And Retail Pharmacies

3) By End-User: Hospitals, Dermatology Clinics, Homecare Settings, Other End-Users

Subsegments:

1) By Topical Treatment: 5-Fluorouracil (5-FU), Imiquimod, Diclofenac

2) By Surgical Procedure: Cryotherapy, Curettage And Electrodessication

3) By Photodynamic Therapy: Aminolevulinic Acid (ALA) Plus Light Therapy, Methyl Aminolevulinate (MAL) Plus Light Therapy

4) By Other Treatment Types: Laser Therapy, Combination Therapies

What Trends Are Shaping The Future Of The Actinic Keratosis Market?

Leading firms within the actinic keratosis market are concentrating their efforts on creating topical ointments aimed at effectively addressing and removing precancerous lesions, lowering recurrence rates, and boosting patient adherence through shorter treatment times and better safety profiles. These topical ointments consist of medicated creams or gels directly applied to the affected skin, containing active ingredients like tirbanibulin, which function by targeting abnormal keratinocytes to manage precancerous lesions. An example of this is in June 2024, when Almirall SA, a biopharmaceutical company based in Spain, obtained approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) allowing the expanded application area for its medication, Klisyri, up to 100 cm2. Klisyri (tirbanibulin) 1% ointment acts as a microtubule inhibitor, formulated to hinder the uncontrolled growth of abnormal keratinocytes, thereby effectively diminishing both the count and dimensions of precancerous lesions in the treatment of actinic keratosis (AK) located on the face or scalp.

Who Are The Companies Competing Within The Actinic Keratosis Market?

Major companies operating in the actinic keratosis market are Galderma SA, LEO Pharma A/S, Almirall S.A., Bausch Health Companies Inc., Perrigo Company plc, Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GSK plc, Amgen Inc., Incyte Corporation, Aclaris Therapeutics Inc., Biofrontera AG, Hill Dermaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Viatris Inc.

Get The Full Actinic Keratosis Market Report:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

Which Region Is The Top Contributor To The Actinic Keratosis Market By Share?

North America was the largest region in the actinic keratosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Actinic Keratosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

Browse Through More Reports Similar to the Global Actinic Keratosis Market 2026, By The Business Research Company

Keloids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Neurotrophic Keratitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Scleroderma Market Report 2026

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Actinic Keratosis Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The actinic keratosis market size has experienced significant expansion in recent years. It is anticipated to increase from $8.42 billion in 2025 to $8.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to factors such as rising UV exposure and sunburn incidence, the limited availability of effective topical agents, increasing skin cancer prevalence, the expansion of dermatology infrastructure, and the adoption of conventional surgical procedures.

The market for actinic keratosis is projected to experience substantial expansion over the coming years, reaching $11.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This anticipated growth during the forecast period is largely driven by factors such as the development of sophisticated photodynamic therapies, a rise in the application of combined topical and procedural treatments, the broadening of hospital and dermatology clinic networks, heightened consumer awareness regarding early intervention, and the introduction of novel homecare treatment options. Key trends observed within the forecast period encompass an increasing emphasis on sun protection and overall skin health awareness, the growing acceptance of non-invasive photodynamic therapy, an increase in the use of topical therapeutics for early-stage actinic keratosis, the expansion of both dermatology clinics and homecare treatment solutions, and a growing inclination towards combination therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21077&type=smp

What Key Drivers Are Influencing The Growth Of The Actinic Keratosis Market?

The actinic keratosis market is projected to expand due to the increasing incidence of severe sunburns. These are intense skin burns, a consequence of excessive exposure to ultraviolet (UV) radiation, which manifest as redness, pain, swelling, and occasionally blistering. Factors contributing to sunburns include prolonged exposure to ultraviolet (UV) radiation, inadequate sun protection measures, greater participation in outdoor activities during peak UV hours, and rising temperatures linked to climate change. Sunburns lead to actinic keratosis by causing DNA damage in skin cells through ultraviolet (UV) radiation, which generates mutations that impair normal cell function, thereby fostering the development of precancerous lesions, particularly with recurrent or extended sun exposure. For instance, in May 2024, according to Melanoma Focus, a UK-based charity, in 2022-23, there were 201 hospital admissions due to sunburn, encompassing 89 children and 25 babies under one year old. The charity additionally found that 66% of UK adults aged 16-65 remembered getting sunburned as children, with 65% of them experiencing severe sunburn with blisters at least once. This number rose to 77% for those with light, pale, or white skin. Consequently, the expanding occurrence of severe sunburns is propelling the growth of the actinic keratosis market.

What Major Segment Divisions Exist Within The Actinic Keratosis Market?

The actinic keratosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatment, Surgical Procedure, Photodynamic Therapy, Other Treatment Types

2) By Distribution Channels: Hospital Pharmacies, Drug Stores And Retail Pharmacies

3) By End-User: Hospitals, Dermatology Clinics, Homecare Settings, Other End-Users

Subsegments:

1) By Topical Treatment: 5-Fluorouracil (5-FU), Imiquimod, Diclofenac

2) By Surgical Procedure: Cryotherapy, Curettage And Electrodessication

3) By Photodynamic Therapy: Aminolevulinic Acid (ALA) Plus Light Therapy, Methyl Aminolevulinate (MAL) Plus Light Therapy

4) By Other Treatment Types: Laser Therapy, Combination Therapies

How Are Trends Shaping The Direction Of The Actinic Keratosis Market?

Companies operating in the actinic keratosis market are intensely focused on developing topical ointments. These efforts aim to effectively target and eliminate precancerous lesions, decrease recurrence rates, and boost patient compliance by offering shorter treatment durations and improved safety profiles. Topical ointments are medicinal creams or gels applied directly to the affected skin, containing active ingredients like tirbanibulin, which function by addressing abnormal keratinocytes to manage precancerous lesions. For example, in June 2024, Almirall SA, a Spain-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA). This approval expands the treatable area for its drug, Klisyri, to up to 100 cm2. Klisyri (tirbanibulin) 1% ointment acts as a microtubule inhibitor, designed to prevent the proliferation of abnormal keratinocytes, thereby effectively reducing the quantity and size of precancerous lesions for the treatment of actinic keratosis (AK) on the face or scalp.

Which Companies Are Leading Innovation In The Actinic Keratosis Market?

Major companies operating in the actinic keratosis market are Galderma SA, LEO Pharma A/S, Almirall S.A., Bausch Health Companies Inc., Perrigo Company plc, Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GSK plc, Amgen Inc., Incyte Corporation, Aclaris Therapeutics Inc., Biofrontera AG, Hill Dermaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Viatris Inc.

Read the full actinic keratosis market report here:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Actinic Keratosis Market?

North America was the largest region in the actinic keratosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Actinic Keratosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21077&type=smp

Browse Through More Reports Similar to the Global Actinic Keratosis Market 2026, By The Business Research Company

neurotrophic keratitis treatment global market report

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

scleroderma global market report

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

keloids treatment global market report

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Actinic Keratosis Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The actinic keratosis market size has experienced significant expansion in recent years. It is anticipated to increase from $8.42 billion in 2025 to $8.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to factors such as rising UV exposure and sunburn incidence, the limited availability of effective topical agents, increasing skin cancer prevalence, the expansion of dermatology infrastructure, and the adoption of conventional surgical procedures.

The market for actinic keratosis is projected to experience substantial expansion over the coming years, reaching $11.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This anticipated growth during the forecast period is largely driven by factors such as the development of sophisticated photodynamic therapies, a rise in the application of combined topical and procedural treatments, the broadening of hospital and dermatology clinic networks, heightened consumer awareness regarding early intervention, and the introduction of novel homecare treatment options. Key trends observed within the forecast period encompass an increasing emphasis on sun protection and overall skin health awareness, the growing acceptance of non-invasive photodynamic therapy, an increase in the use of topical therapeutics for early-stage actinic keratosis, the expansion of both dermatology clinics and homecare treatment solutions, and a growing inclination towards combination therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21077&type=smp

What Key Drivers Are Influencing The Growth Of The Actinic Keratosis Market?

The actinic keratosis market is projected to expand due to the increasing incidence of severe sunburns. These are intense skin burns, a consequence of excessive exposure to ultraviolet (UV) radiation, which manifest as redness, pain, swelling, and occasionally blistering. Factors contributing to sunburns include prolonged exposure to ultraviolet (UV) radiation, inadequate sun protection measures, greater participation in outdoor activities during peak UV hours, and rising temperatures linked to climate change. Sunburns lead to actinic keratosis by causing DNA damage in skin cells through ultraviolet (UV) radiation, which generates mutations that impair normal cell function, thereby fostering the development of precancerous lesions, particularly with recurrent or extended sun exposure. For instance, in May 2024, according to Melanoma Focus, a UK-based charity, in 2022-23, there were 201 hospital admissions due to sunburn, encompassing 89 children and 25 babies under one year old. The charity additionally found that 66% of UK adults aged 16-65 remembered getting sunburned as children, with 65% of them experiencing severe sunburn with blisters at least once. This number rose to 77% for those with light, pale, or white skin. Consequently, the expanding occurrence of severe sunburns is propelling the growth of the actinic keratosis market.

What Major Segment Divisions Exist Within The Actinic Keratosis Market?

The actinic keratosis market covered in this report is segmented –

1) By Treatment Type: Topical Treatment, Surgical Procedure, Photodynamic Therapy, Other Treatment Types

2) By Distribution Channels: Hospital Pharmacies, Drug Stores And Retail Pharmacies

3) By End-User: Hospitals, Dermatology Clinics, Homecare Settings, Other End-Users

Subsegments:

1) By Topical Treatment: 5-Fluorouracil (5-FU), Imiquimod, Diclofenac

2) By Surgical Procedure: Cryotherapy, Curettage And Electrodessication

3) By Photodynamic Therapy: Aminolevulinic Acid (ALA) Plus Light Therapy, Methyl Aminolevulinate (MAL) Plus Light Therapy

4) By Other Treatment Types: Laser Therapy, Combination Therapies

How Are Trends Shaping The Direction Of The Actinic Keratosis Market?

Companies operating in the actinic keratosis market are intensely focused on developing topical ointments. These efforts aim to effectively target and eliminate precancerous lesions, decrease recurrence rates, and boost patient compliance by offering shorter treatment durations and improved safety profiles. Topical ointments are medicinal creams or gels applied directly to the affected skin, containing active ingredients like tirbanibulin, which function by addressing abnormal keratinocytes to manage precancerous lesions. For example, in June 2024, Almirall SA, a Spain-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA). This approval expands the treatable area for its drug, Klisyri, to up to 100 cm2. Klisyri (tirbanibulin) 1% ointment acts as a microtubule inhibitor, designed to prevent the proliferation of abnormal keratinocytes, thereby effectively reducing the quantity and size of precancerous lesions for the treatment of actinic keratosis (AK) on the face or scalp.

Which Companies Are Leading Innovation In The Actinic Keratosis Market?

Major companies operating in the actinic keratosis market are Galderma SA, LEO Pharma A/S, Almirall S.A., Bausch Health Companies Inc., Perrigo Company plc, Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GSK plc, Amgen Inc., Incyte Corporation, Aclaris Therapeutics Inc., Biofrontera AG, Hill Dermaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Viatris Inc.

Read the full actinic keratosis market report here:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Actinic Keratosis Market?

North America was the largest region in the actinic keratosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Actinic Keratosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21077&type=smp

Browse Through More Reports Similar to the Global Actinic Keratosis Market 2026, By The Business Research Company

neurotrophic keratitis treatment global market report

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

scleroderma global market report

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

keloids treatment global market report

https://www.thebusinessresearchcompany.com/report/keloids-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model